Bio-Rad Laboratories, Inc. BIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +22.84%
- 1 year
- +22.18%
- Open
- 381.09
- Prev close
- 384.40
- Mkt cap
- 9.96B
- Vol
- 183.09K
- Avg vol
- 255.45K
- EPS
- 7.89
- P/E
- 47.17
- Div yield
- 0.00%
More statistics
- Low
- 368.45
- High
- 381.29
- Forward P/E
- 38.14
- Beta
- 1.07
- Short ratio
- 4.17
- Inst. own
- 91.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 374.89
- 200-d avg
- 313.14
- 1y target
- 335.00
5D chart
Signals (139)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:25 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:00 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:20 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:20 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:50 AM | 6 days ago |
News
2 days ago businesswire.com
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief…
4 days ago globenewswire.com
BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem
RIYADH, Saudi Arabia and HOLMDEL, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global provider of Identity and Access Management (IAM) and biometric…
4 days ago seekingalpha.com
Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds…
6 days ago seekingalpha.com
Ariel Fund Q3 2026 Leaders And Laggards
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology…
1 week ago globenewswire.com
BIO-key Secures Another Middle East Government Contract for its Passwordless, Biometric, Identity and Access Management Solutions
BIO-key (BKYI) secured another Middle East government contract (new customer) for its passwordless, biometric, identity & access management (IAM) solutions
2 weeks ago gurufocus.com
Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100
On October 16, 2026, Bio-Rad Laboratories Inc (BIO) shares fell by 3.0%, bringing the current price to $353.70. The stock has experienced a 52-week range of $23
2 weeks ago businesswire.com
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for…
2 weeks ago globenewswire.com
BIO-key Names Cybersecurity Veteran Stephen Morrow President of PortalGuard to Drive Accelerated Adoption of its Innovative IAM Solution
HOLMDEL, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring…
2 weeks ago globenewswire.com
BIO-key Adds New Middle East Government Security Agency Customer, Expanding Regional Footprint
BIO-key (BKYI) Adds New Middle East Government Security Agency, Expands Regional Footprint, Supports National Digital Transformation & Cybersecurity goals.
3 weeks ago globenewswire.com
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
3 weeks ago globenewswire.com
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS,…
1 month ago globenewswire.com
BIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf
BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.
1 month ago marketbeat.com
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a…
1 month ago seekingalpha.com
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
1 month ago zacks.com
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
1 month ago globenewswire.com
BIO-key Receives FIDO Alliance Full Certification for Passkey:YOU™ Authentication, Unlocking New Markets Including Agentic AI Authenticated Controls
HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring…
1 month ago businesswire.com
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief…
1 month ago defenseworld.net
California State Teachers Retirement System Has $1.79 Billion Position in Bio-Rad Laboratories, Inc. $BIO
California State Teachers Retirement System boosted its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 27,700.0% during the second quarter, according to its most recent disclosure with the…
1 month ago seekingalpha.com
Bio-Rad: Favorable Read-Across From Investor Event
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%,…
1 month ago seekingalpha.com
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390
RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
-
2 months ago benzinga.com
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330
Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370
RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330
Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
-
2 months ago benzinga.com
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
-
2 months ago benzinga.com
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of…
5 months ago benzinga.com
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.
5 months ago benzinga.com
Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and the 10-year yield hovers near 4.6% on stalled US-Iran talks.
5 months ago benzinga.com
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
-
5 months ago benzinga.com
'Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad' - WSJ
https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-bio-rad-c99b23fa
-
5 months ago benzinga.com
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target
RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
6 months ago benzinga.com
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU
U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.
-
6 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
-
6 months ago benzinga.com
Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
6 months ago benzinga.com
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
-
6 months ago benzinga.com
Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of…
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
-
6 months ago benzinga.com
Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
8 months ago benzinga.com
Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
8 months ago benzinga.com
Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est
Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5…
8 months ago benzinga.com
Earnings Summary: Bio-Rad Laboratories Q4
Earnings Summary: Bio-Rad Laboratories Q4
-
8 months ago benzinga.com
Bio-Rad Laboratories Q4 Adj. EPS $2.51 Misses $2.70 Estimate, Sales $693.200M Beat $688.758M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 12, 2026
Earnings Scheduled For February 12, 2026
9 months ago benzinga.com
Qiagen Explores Possible Sale After New Buyer Talks: Report
Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.
-
1 year ago benzinga.com
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
-
1 year ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $265 to $340.
-
1 year ago benzinga.com
CORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.93 by 16.92 percent. This is a 11.88 percent increase over earnings of…
-
1 year ago benzinga.com
Bio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est
Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to…
1 year ago benzinga.com
Earnings Scheduled For October 29, 2025
Earnings Scheduled For October 29, 2025